fda
Unplanned entry points, access routes blamed
FDA 周一表示,GLP-1 药物生产商须在产品标签上增加一项可能导致突然失明的警示。被称为非动脉炎性前部缺血性视神经病变(nonarteritic anterior ischemic optic neuropathy,NAION)的眼部疾病会影响视神经——负责将信号从眼睛传输至大脑的神经。当流向视神经的血液减少或受阻…
President Donald Trump's FDA pick, Heidi Overton, saw her nomination pulled one day before a Senate committee vote, a White House official confirmed.
ABD Gıda ve İlaç Dairesi (FDA), İsviçreli ilaç üreticisi Roche'un geliştirdiği Wilserdly adlı yeni meme kanseri ilacına pazartesi günü onay verdi. Giredestrant …
Haven't you heard? Myke had COVID.
The risk appears small and data is mixed, but FDA wants patients to be aware.
“It should be an even playing field,” Sal Mancuso told Fortune, “not a playing field where bad actors are in a better position than responsible companies like o…
The data on which the FDA’s warning is based suggests a real but low risk of NAION for people taking GLP-1 medications.
In July 2026 the committee voted 8-6 to expand access to six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.





